Loading startup
Market data is refreshed once per day from public sources. Information may be incomplete or outdated — verify independently before making decisions. This is not investment advice.
Evidence-bound summary — expand sections for movement, risks, and signals.
Memo snapshot · Jun 28, 2026, 6:32 PM
What would change this read
DealFlow OS uses public web data and automated enrichment. Research may be incomplete, outdated, or incorrect. Verify important information before making investment or outreach decisions.
TL;DR
Seed (YC)Ritivel Regulatory document automation for pharma.
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
Funding
Raised $500K across 1 funding round. Latest: $500K Pre-seed (Jan 2026). Investors: Y Combinator. (High).
Product / news
5 product/news‑styled row(s); headline risk without filings (High).
Verified facts
+3 more in Recent movement below
Winter 2026 (W26) batch. AI-native regulatory platform drafting life-sciences submissions in minutes.
Weak funding evidence: mention does not include a parsed raise amount/round and may refer to non-funding context.
No open roles indexed yet.
The index price and activity score are algorithmic estimates based on observed public company-level signals. They may be incomplete, stale, or inaccurate and are not investment, legal, tax, or business advice.
Source types found
Strongest / recent news-style rows
About page · Thu, Jul 2, 04:27 PM · confidence 90%high quality
Wed, May 20, 06:12 PM · confidence 88%high quality
Wed, May 20, 06:12 PM · confidence 85%medium quality
Newest first · 11 event(s)
Source: Blog
Stay updated with the latest insights on AI in drug development, regulatory automation, and life sciences innovation from the Ritivel team.
Source: About page
Ritivel is building the AI-native regulatory platform for life sciences. Backed by Y Combinator, built by experts from Microsoft and Kearney.
Source: Homepage
Draft Clinical Study Reports in minutes, not weeks. AI-native regulatory platform with 100% reproducibility and word-level traceability.
Winter 2026 (W26) batch. AI-native regulatory platform drafting life-sciences submissions in minutes.
Source: Blog / news
Standard retrieval fails on 50% of queries involving similar drug names. Context-enriched retrieval cuts that failure rate by 80%. Here's what we learned building a benchmark to test it.
Source: Blog / news
A data-driven analysis of the 2026 J.P. Morgan Healthcare Conference. $116B in M&A, $180B at risk from patent cliffs, and the trends reshaping drug development.
Source: Blog / news
A detailed breakdown of the 10 joint EMA-FDA principles for AI in drug development. Includes definitions of key technical terms like GxP, data drift, and model validation.
Source: Blog / news
Examining the latest published data on clinical trial success rates by phase, therapeutic area, and development timeline. What the numbers tell us about where drugs succeed and fail.
Draft clinical study reports in minutes.
1 row(s)
The company's own site — the authoritative description of what they sell and to whom. Marketing-controlled, so treat claims as positioning rather than verified traction.
Draft Clinical Study Reports in minutes, not weeks. AI-native regulatory platform with 100% reproducibility and word-level traceability.
Why it matters: Primary source — the company's own positioning; best read for what they sell and to whom, not for traction claims.
Open source ↗4 row(s)
Third-party press coverage. Independent reporting corroborates company claims; repeated coverage across outlets is a momentum signal.
Ritivel is building the AI-native regulatory platform for life sciences. Backed by Y Combinator, built by experts from Microsoft and Kearney.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Draft clinical study reports in minutes.
Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗Why it matters: Independent coverage — third-party corroboration of company claims; recurring coverage indicates rising visibility.
Open source ↗1 row(s)
Funding announcements and investor-database records. The strongest public signal of capitalization: round, amount, and syndicate quality when disclosed.
Winter 2026 (W26) batch. AI-native regulatory platform drafting life-sciences submissions in minutes.
Why it matters: Funding signal — Pre-Seed per this source; verify against the linked original before relying on it.
Open source ↗5 row(s)
Company blog and newsletters. Shipping cadence and technical depth of posts hint at product velocity and team quality.
Stay updated with the latest insights on AI in drug development, regulatory automation, and life sciences innovation from the Ritivel team.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Standard retrieval fails on 50% of queries involving similar drug names. Context-enriched retrieval cuts that failure rate by 80%. Here's what we learned building a benchmark to test it.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗A data-driven analysis of the 2026 J.P. Morgan Healthcare Conference. $116B in M&A, $180B at risk from patent cliffs, and the trends reshaping drug development.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗A detailed breakdown of the 10 joint EMA-FDA principles for AI in drug development. Includes definitions of key technical terms like GxP, data drift, and model validation.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Examining the latest published data on clinical trial success rates by phase, therapeutic area, and development timeline. What the numbers tell us about where drugs succeed and fail.
Why it matters: Company publishing — post cadence and depth hint at product velocity.
Open source ↗Sign in as an active team member to view private notes, watchlist controls, transcript evidence, and interaction history.